Mesenchymal stem cells: A new promise in anticancer therapy

Stem Cells and Development

Volumn 20, Issue 1, 2011, Pages 1-10

  Ciavarella, Sabino ^a   Dominici, Massimo ^a   Dammacco, Franco ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BREAST CANCER; CANCER GENE THERAPY; CANCER THERAPY; CELL HOMING; COLON CANCER; EWING SARCOMA; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LUNG CANCER; LUNG METASTASIS; MELANOMA; MESENCHYMAL STEM CELL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMACH CANCER; TISSUE REPAIR; UTERINE CERVIX CARCINOMA;

ANIMALS; GENE THERAPY; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; NEOPLASMS;

EID: 78650994866     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2010.0223     Document Type: Review

References (84)

1. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop, and E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317.
2. Schafer R, M Dominici, I Muller, F Dazzi, K Bieback, K Godthardt, K Le Blanc, R Meisel, R Pochampally, R Richter, T Skutella, G Steinhoff, M Mitterberger, H Wendel, J Wiskirchen, R Handgretinger, and H Northoff. (2007). Progress in characterization, preparation and clinical applications of non-hematopoietic stem cells, 29-30 September 2006, Tubingen, Germany. Cytotherapy 9:397-405.
3. Horwitz EM and M Dominici. (2008). How do mesenchymal stromal cells exert their therapeutic benefit? Cytotherapy 10:771-774.
4. Uccelli A, L Moretta, and V Pistoia. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726-736.
5. Ponte AL, E Marais, N Gallay, A Langonne, B Delorme, O Herault, P Charbord, and J Domenech. (2007). The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 25:1737-1745.
6. Khakoo AY, S Pati, SA Anderson, W Reid, MF Elshal, Rovira, II, AT Nguyen, D Malide, CA Combs, G Hall, J Zhang, M Raffeld, TB Rogers, W Stetler-Stevenson, JA Frank, M Reitz, and T Finkel. (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposis sarcoma. J Exp Med 203:1235-1247. (Pubitemid 43736593)
7. Claros S, M Alonso, J Becerra, and JA Andrades. (2008). Selection and induction of rat skeletal muscle-derived cells to the chondro-osteogenic lineage. Cell Mol Biol (Noisy-legrand) 54:1-10.
8. De Coppi P, M Pozzobon, M Piccoli, MV Gazzola, L Boldrin, E Slanzi, R Destro, L Zanesco, GF Zanon, and P Gamba. (2006). Isolation of mesenchymal stem cells from human vermiform appendix. J Surg Res 135:85-91.
9. Huang GT, S Gronthos, and S Shi. (2009). Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. J Dent Res 88:792-806.
10. Jones EA, A Crawford, A English, K Henshaw, J Mundy, D Corscadden, T Chapman, P Emery, P Hatton, and D McGonagle. (2008). Synovial fluid mesenchymal stem cells in health and early osteoarthritis: detection and functional evaluation at the single-cell level. Arthritis Rheum 58:1731-1740.
11. Song L, NJ Young, NE Webb, and RS Tuan. (2005). Origin and characterization of multipotential mesenchymal stem cells derived from adult human trabecular bone. Stem Cells Dev 14:712-721.
12. Zuk PA, M Zhu, H Mizuno, J Huang, JW Futrell, AJ Katz, P Benhaim, HP Lorenz, and MH Hedrick. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:211-228.
13. Secco M, E Zucconi, NM Vieira, LL Fogaca, A Cerqueira, MD Carvalho, T Jazedje, OK Okamoto, AR Muotri, and M Zatz. (2008). Multipotent stem cells from umbilical cord: cord is richer than blood! Stem Cells 26:146-150.
14. Parolini O, F Alviano, GP Bagnara, G Bilic, HJ Buhring, M Evangelista, S Hennerbichler, B Liu, M Magatti, N Mao, T Miki, F Marongiu, H Nakajima, T Nikaido, CB Portmann-Lanz, V Sankar, M Soncini, G Stadler, D Surbek, TA Takahashi, H Redl, N Sakuragawa, S Wolbank, S Zeisberger, A Zisch, and SC Strom. (2008). Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells 26:300-311.
15. De Coppi P, G Bartsch Jr., MM Siddiqui, T Xu, CC Santos, L Perin, G Mostoslavsky, AC Serre, EY Snyder, JJ Yoo, ME Furth, S Soker, and A Atala. (2007). Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 25:100-106.
16. Ciavarella S, F Dammacco, M De Matteo, G Loverro, and F Silvestris. (2009). Umbilical cord mesenchymal stem cells: role of regulatory genes in their differentiation to osteoblasts. Stem Cells Dev 18:1211-1220.
17. ODonoghue K and J Chan. (2006). Human fetal mesenchymal stem cells. Curr Stem Cell Res Ther 1:371-386.
18. Suck G, DR Branch, MJ Smyth, RG Miller, J Vergidis, S Fahim, and A Keating. (2005). KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol 33:1160-1171.
19. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig, and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
20. Uccelli A, L Moretta, and V Pistoia. (2006). Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 36:2566-2573. (Pubitemid 44608440)
21. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti, and AM Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843.
22. Tse WT, JD Pendleton, WM Beyer, MC Egalka, and EC Guinan. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75:389-397.
23. Bartholomew A, C Sturgeon, M Siatskas, K Ferrer, K McIntosh, S Patil, W Hardy, S Devine, D Ucker, R Deans, A Moseley, and R Hoffman. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30:42-48.
24. Le Blanc K, C Tammik, K Rosendahl, E Zetterberg, and O Ringden. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31:890-896.
25. Krampera M, S Glennie, J Dyson, D Scott, R Laylor, E Simpson, and F Dazzi. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigenspecific T cells to their cognate peptide. Blood 101:3722-3729.
26. Klyushnenkova E, JD Mosca, V Zernetkina, MK Majumdar, KJ Beggs, DW Simonetti, RJ Deans, and KR McIntosh. (2005). T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12:47-57.
27. Corcione A, F Benvenuto, E Ferretti, D Giunti, V Cappiello, F Cazzanti, M Risso, F Gualandi, GL Mancardi, V Pistoia, and A Uccelli. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372.
28. Jiang XX, Y Zhang, B Liu, SX Zhang, Y Wu, XD Yu, and N Mao. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105:4120-4126.
29. Prasanna SJ, D Gopalakrishnan, SR Shankar, and AB Vasandan. (2010). Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 5:e9016.
30. Wang M, Y Yang, D Yang, F Luo, W Liang, S Guo, and J Xu. (2009). The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology 126:220-232.
31. Devine SM, C Cobbs, M Jennings, A Bartholomew, and R Hoffman. (2003). Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101:2999-3001.
32. Chen J, Y Li, L Wang, M Lu, X Zhang, and M Chopp. (2001). Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci 189:49-57. (Pubitemid 32776649)
33. Li Y, J Chen, L Wang, L Zhang, M Lu, and M Chopp. (2001). Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinsons disease. Neurosci Lett 316:67-70. (Pubitemid 34001662)
34. Kawada H, J Fujita, K Kinjo, Y Matsuzaki, M Tsuma, H Miyatake, Y Muguruma, K Tsuboi, Y Itabashi, Y Ikeda, S Ogawa, H Okano, T Hotta, K Ando, and K Fukuda. (2004). Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 104:3581-3587.
35. Dezawa M, H Ishikawa, Y Itokazu, T Yoshihara, M Hoshino, S Takeda, C Ide, and Y Nabeshima. (2005). Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 309:314-317.
36. Karp JM and GS Leng Teo. (2009). Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4:206-216.
37. Ries C, V Egea, M Karow, H Kolb, M Jochum, and P Neth. (2007). MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 109:4055-4063.
38. Rombouts WJ and RE Ploemacher. (2003). Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 17:160-170.
39. Wynn RF, CA Hart, C Corradi-Perini, L ONeill, CA Evans, JE Wraith, LJ Fairbairn, and I Bellantuono. (2004). A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104:2643-2645.
40. Shi M, J Li, L Liao, B Chen, B Li, L Chen, H Jia, and RC Zhao. (2007). Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD=SCID mice. Haematologica 92:897-904.
41. Dvorak HF. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659.
42. Houghton J, C Stoicov, S Nomura, AB Rogers, J Carlson, H Li, X Cai, JG Fox, JR Goldenring, and TC Wang. (2004). Gastric cancer originating from bone marrow-derived cells. Science 306:1568-1571.
43. Komarova S, Y Kawakami, MA Stoff-Khalili, DT Curiel, and L Pereboeva. (2006). Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 5:755-766.
44. Kosztowski T, HA Zaidi, and A Quinones-Hinojosa. (2009). Applications of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev Anticancer Ther 9:597-612.
45. Zhu W, W Xu, R Jiang, H Qian, M Chen, J Hu, W Cao, C Han, and Y Chen. (2006). Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 80:267-274.
46. Fierro FA, WD Sierralta, MJ Epunan, and JJ Minguell. (2004). Marrow-derived mesenchymal stem cells: role in epithelial tumor cell determination. Clin Exp Metastasis 21:313-319.
47. Djouad F, P Plence, C Bony, P Tropel, F Apparailly, J Sany, D Noel, and C Jorgensen. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102:3837-3844.
48. Kaplan RN, B Psaila, and D Lyden. (2006). Bone marrow cells in the pre-metastatic niche: within bone and beyond. Cancer Metastasis Rev 25:521-529.
49. Karnoub AE, AB Dash, AP Vo, A Sullivan, MW Brooks, GW Bell, AL Richardson, K Polyak, R Tubo, and RA Weinberg. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557-563.
50. Maestroni GJ, E Hertens, and P Galli. (1999). Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci 55:663-667.
51. Ohlsson LB, L Varas, C Kjellman, K Edvardsen, and M Lindvall. (2003). Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol 75:248-255.
52. Pisati F, M Belicchi, F Acerbi, C Marchesi, C Giussani, M Gavina, S Javerzat, M Hagedorn, G Carrabba, V Lucini, SM Gaini, N Bresolin, L Bello, A Bikfalvi, and Y Torrente. (2007). Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models. Cancer Res 67:3054-3063.
53. Nakamizo A, F Marini, T Amano, A Khan, M Studeny, J Gumin, J Chen, S Hentschel, G Vecil, J Dembinski, M Andreeff, and FF Lang. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307-3318.
54. Ren C, S Kumar, D Chanda, L Kallman, J Chen, JD Mountz, and S Ponnazhagan. (2008). Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther 15:1446-1453.
55. Studeny M, FC Marini, RE Champlin, C Zompetta, IJ Fidler, and M Andreeff. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:3603-3608.
56. Studeny M, FC Marini, JL Dembinski, C Zompetta, M Cabreira-Hansen, BN Bekele, RE Champlin, and M Andreeff. (2004). Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:1593-1603.
57. Ren C, S Kumar, D Chanda, J Chen, JD Mountz, and S Ponnazhagan. (2008). Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 26:2332-2338.
58. Duan X, H Guan, Y Cao, and ES Kleinerman. (2009). Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer 115:13-22.
59. Elzaouk L, K Moelling, and J Pavlovic. (2006). Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 15:865-874.
60. Gao P, Q Ding, Z Wu, H Jiang, and Z Fang. (2010). Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 290:157-166.
61. Nakamura K, Y Ito, Y Kawano, K Kurozumi, M Kobune, H Tsuda, A Bizen, O Honmou, Y Niitsu, and H Hamada. (2004). Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11:1155-1164.
62. Xu G, XD Jiang, Y Xu, J Zhang, FH Huang, ZZ Chen, DX Zhou, JH Shang, YX Zou, YQ Cai, SB Kou, YZ Chen, RX Xu, and YJ Zeng. (2009). Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol Int 33: 466-474.
63. Yuan X, J Hu, ML Belladonna, KL Black, and JS Yu. (2006). Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res 66:2630-2638.
64. Cavarretta IT, V Altanerova, M Matuskova, L Kucerova, Z Culig, and C Altaner. (2010). Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 18:223-231.
65. Kanehira M, H Xin, K Hoshino, M Maemondo, H Mizuguchi, T Hayakawa, K Matsumoto, T Nakamura, T Nukiwa, and Y Saijo. (2007). Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther 14:894-903. (Pubitemid 47557220)
66. Kucerova L, V Altanerova, M Matuskova, S Tyciakova, and C Altaner. (2007). Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 67:6304-6313.
67. Kucerova L, M Matuskova, A Pastorakova, S Tyciakova, J Jakubikova, R Bohovic, V Altanerova, and C Altaner. (2008). Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 10:1071-1082.
68. Matuskova M, K Hlubinova, A Pastorakova, L Hunakova, V Altanerova, C Altaner, and L Kucerova. (2010). HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett 290:58-67.
69. You MH, WJ Kim, W Shim, SR Lee, G Lee, S Choi, DY Kim, YM Kim, H Kim, and SU Han. (2009). Cytosine deaminaseproducing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model. J Gastroenterol Hepatol 24:1393-1400.
70. Zischek C, H Niess, I Ischenko, C Conrad, R Huss, KW Jauch, PJ Nelson, and C Bruns. (2009). Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 250:747-753.
71. Menon LG, K Kelly, HW Yang, SK Kim, PM Black, and RS Carroll. (2009). Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 27:2320-2330.
72. Mohr A, M Lyons, L Deedigan, T Harte, G Shaw, L Howard, F Barry, T OBrien, and R Zwacka. (2008). Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 12(6B):2628-2643.
73. Carlo-Stella C, C Lavazza, A Locatelli, L Vigano, AM Gianni, and L Gianni. (2007). Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 13:2313-2317.
74. Sasportas LS, R Kasmieh, H Wakimoto, S Hingtgen, JA van de Water, G Mohapatra, JL Figueiredo, RL Martuza, R Weissleder, and K Shah. (2009). Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106:4822-4827.
75. Yang B, X Wu, Y Mao,WBao, L Gao, P Zhou, R Xie, L Zhou, and J Zhu. (2009). Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Neurosurgery 65:610-624; discussion 624.
76. Loebinger MR, A Eddaoudi, D Davies, and SM Janes. (2009). Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 69:4134-4142.
77. Grisendi G, R Bussolari, L Cafarelli, I Petak, V Rasini, E Veronesi, G De Santis, C Spano, M Tagliazzucchi, H Barti-Juhasz, L Scarabelli, F Bambi, A Frassoldati, G Rossi, C Casali, U Morandi, EM Horwitz, P Paolucci, P Conte, and M Dominici. (2010). Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosisinducing ligand delivery for cancer therapy. Cancer Res 70:3718-3729.
78. Kim SM, JY Lim, SI Park, CH Jeong, JH Oh, M Jeong, W Oh, SH Park, YC Sung, and SS Jeun. (2008). Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 68:9614-9623.
79. Burger JA, P Ghia, A Rosenwald, and F Caligaris-Cappio. (2009). The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114:3367-3375.
80. Carlo-Stella C, C Lavazza, M Di Nicola, L Cleris, P Longoni, M Milanesi, M Magni, D Morelli, A Gloghini, A Carbone, and AM Gianni. (2006). Antitumor activity of human CD34 cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther 17:1225-1240.
81. Lavazza C, C Carlo-Stella, A Giacomini, L Cleris, M Righi, D Sia, M Di Nicola, M Magni, P Longoni, M Milanesi, M Francolini, A Gloghini, A Carbone, F Formelli, and AM Gianni. (2010). Human CD34 cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood 115:2231-2240.
82. Bergfeld SA and YA Declerck. (2010). Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 29:249-261.
83. Rabin N, C Kyriakou, L Coulton, OM Gallagher, C Buckle, R Benjamin, N Singh, J Glassford, T Otsuki, AC Nathwani, PI Croucher, and KL Yong. (2007). A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia 21: 2181-2191.
84. Mukherjee S, N Raje, JA Schoonmaker, JC Liu, T Hideshima, MN Wein, DC Jones, S Vallet, ML Bouxsein, S Pozzi, S Chhetri, YD Seo, JP Aronson, C Patel, M Fulciniti, LE Purton, LH Glimcher, JB Lian, G Stein, KC Anderson, and DT Scadden. (2008). Pharmacologic targeting of a stem= progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118:491-504.